Abstract:Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), is an untreatable autosomal dominant neurodegenerative disease, and the most common such inherited ataxia worldwide. The mutation in SCA3 is the expansion of a polymorphic CAG tri-nucleotide repeat sequence in the C-terminal coding region of the ATXN3 gene at chromosomal locus 14q32.1. The mutant ATXN3 protein encoding expanded glutamine (polyQ) sequences interacts with multiple proteins in vivo, and is deposited as aggregates in the SCA3 brain. A large body of literature suggests that the loss of function of the native ATNX3-interacting proteins that are deposited in the polyQ aggregates contributes to cellular toxicity, systemic neurodegeneration and the pathogenic mechanism in SCA3. Nonetheless, a significant understanding of the disease etiology of SCA3, the molecular mechanism by which the polyQ expansions in the mutant ATXN3 induce neurodegeneration in SCA3 has remained elusive. In the present study, we show that the essential DNA strand break repair enzyme PNKP (polynucleotide kinase 3'-phosphatase) interacts with, and is inactivated by, the mutant ATXN3, resulting in inefficient DNA repair, persistent accumulation of DNA damage/strand breaks, and subsequent chronic activation of the DNA damage-response ataxia telangiectasia-mutated (ATM) signaling pathway in SCA3. We report that persistent accumulation of DNA damage/strand breaks and chronic activation of the serine/threonine kinase ATM and the downstream p53 and protein kinase C-δ pro-apoptotic pathways trigger neuronal dysfunction and eventually neuronal death in SCA3. Either PNKP overexpression or pharmacological inhibition of ATM dramatically blocked mutant ATXN3-mediated cell death. Discovery of the mechanism by which mutant ATXN3 induces DNA damage and amplifies the pro-death signaling pathways provides a molecular basis for neurodegeneration due to PNKP inactivation in SCA3, and for the first time offers a possible approach to treatment.

Phosphorylation of ataxin-3 by glycogen synthase kinase 3beta at serine 256 regulates the aggregation of ataxin-3

Phosphorylation of Ataxin-3 by Glycogen Synthase Kinase 3β at Serine 256 Regulates the Aggregation of Ataxin-3

Research on Screening and Identification of Proteins Interacting with Ataxin-3.

Casein Kinase 2 Interacts with and Phosphorylates Ataxin-3

PolyQ-expanded Ataxin-3 Interacts with Full-Length Ataxin-3 in a Polyq Length-Dependent Manner

The deubiquitinase function of ataxin-3 and its role in the pathogenesis of Machado-Joseph disease and other diseases

Fibril-forming motif of non-expanded ataxin-3 revealed by scanning proline mutagenesis

Ataxin-3, the MJD1 Gene Product, Interacts with the Two Human Homologs of Yeast DNA Repair Protein RAD23, HHR23A and HHR23B

Polyglutamine-expanded ataxin-3 is degraded by autophagy

Sumo-1 Modification On K166 Of Polyq-Expanded Ataxin-3 Strengthens Its Stability And Increases Its Cytotoxicity

Ubiquitin-interacting motifs of ataxin-3 regulate its polyglutamine toxicity through Hsc70-4-dependent aggregation

Chemical chaperones reduce aggregate formation and cell death caused by the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch

p62/sequestosome 1 regulates aggresome formation of pathogenic ataxin-3 with expanded polyglutamine.

Toward understanding Machado–Joseph disease

Covalent modification of ataxin-3 by SUMO-1

The role of the mammalian DNA end-processing enzyme polynucleotide kinase 3'-phosphatase in spinocerebellar ataxia type 3 pathogenesis

Polyglutamine-expanded Ataxin3 Alter Specific Gene Expressions Through Changing DNA Methylation Status in SCA3/MJD

Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3

Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics

Aggregation of Polyglutamine-Expanded Ataxin-3 Sequesters Its Specific Interacting Partners into Inclusions: Implication in a Loss-of-function Pathology

p45, an ATPase subunit of the 19S proteasome, targets the polyglutamine disease protein ataxin-3 to the proteasome.